twitter twitter

Bio Ascend

Symposium Agenda

Day 1 - Friday, April 19
Day 2 - Saturday, April 20

Times below are in Central Time

Friday, April 19

7:00 AM
Registration, Breakfast & Exhibits
Interprofessional Session (8:00 AM - 11:30 AM)
8:00 AM
Welcome, Introductions and Presession ARS
Andrew Evens, DO, MBA, MSC
Mini Symposium on Bispecifics (8:15 AM – 9:55 AM) • Moderator: Kirk Cahill, MD
8:15 AM
Overview of Bispecific Antibodies: Comparing and Contrasting Current and Emerging Agents
Tara McCabe, APN-BC, AOCNP
8:45 AM
Practical Aspects of Bispecifics: Supportive Care Strategies
Kaitlin Kelly, PharmD, BCOP
9:15 AM
Panel Discussion, Q&A, and Postsession ARS
9:25 AM
Supportive Care for Patients with HL Receiving Immunotherapy: Differentiating Checkpoint Inhibitors vs Antibody-Drug Conjugates
Rebecca Follenweider, BSN, RN, OCN
9:40AM
Panel Discussion with Cases
Rebecca Follenweider, BSN, RN, OCN, Kaitlin Kelly, PharmD, BCOP, and Grace Rivera, MSN, AGPCNP-BC
9:55 AM
Break & Exhibits
Mini Symposium on Advanced Technology in Cancer Care (10:15 AM – 11:30 AM) Moderator: Neha Mehta-Shah, MD, MSCI
10:15 AM
Presession ARS
10:25 AM
Artificial Intelligence and Computational Oncology
Frederick Howard, MD
10:50 AM
Primer on CRISPR and its Impact on Cancer Research and Treatment
Justin Kline, MD
11:20 AM
Panel Discussion, Q&A, and Postsession ARS
11:30 AM
Lunch and Exhibits
General Session
1:00 PM
Welcome and Introductions
Sonali Smith, MD, FASCO
Mini Symposium on T-cell Lymphoma (1:05 PM – 2:30 PM) • Moderator: Sonali Smith, MD, FASCO
1:05 PM
Presession ARS
1:10 PM
Epigenetics in T-cell Lymphoma: Has the Promise Been Fulfilled?
Enrica Marchi, MD
1:30 PM
Novel Therapeutics for T-cell Lymphoma and Lessons Learned from the Current Regulatory Environment
Swaminathan Iyer, MD
1:50 PM
Management of Advanced CTCL
Neha Mehta-Shah, MD, MSCI
2:10 PM
Panel Discussion, Q&A, and Postsession ARS
2:30 PM
Break and Exhibits
Hematopathology Tumor Board (2:50 PM – 4:00 PM) • Moderator: Andrew Evens, DO, MBA, MSc
2:50 PM
Hematopathology Tumor Board
Girish Venkataraman, MD; Kirk Cahill, MD; Anamarija Perry, MD
Mini Symposium on the Management of Bispecifics (4:00 PM - 5:10 PM) • Moderator: Reem Karmali, MD
4:00 PM
Presession ARS
4:05 PM
Bispecifics for LBCL: Focus on Management of Toxicities in the Community
Jennifer Crombie, MD
4:25 PM
Bispecifics for FL
David Russler-Germain, MD, PhD
4:45 PM
Sequencing of Bispecifics with Other Therapies
Elizabeth Budde, MD, PhD
5:05 PM
Panel Discussion, Q&A and Postsession ARS
5:20 PM
Wrap-Up and Summary • Moderator: Timothy Fenske, MD, MS
Welcome & Poster Reception with Exhibitors (5:30 PM - 6:30 PM)

Times below are in Central Time

Saturday, April 20

7:00 AM
Registration, Breakfast & Exhibits
General Session
8:00 AM
Welcome and Introductions
Neha Mehta-Shah, MD, MSCI
8:05 AM
Moderator: Ruemu Birhiray, MD
DEI Keynote Presentation: Implementation of Reducing Barriers to Accessing Lymphoma Care
Christopher Flowers, MD, MS
8:25 AM
Q&A
Mini Symposium on Hodgkin Lymphoma (8:30 AM - 10:10 AM) • Moderator: Andrew Evens, DO, MBA, MSc
8:30 AM
Presession ARS
8:35 AM
Ensuring the Progress in Hodgkin Lymphoma Applies to All Patients
Justine Kahn, MD
8:55 AM
Are Checkpoint Inhibitors the Standard of Care for Frontline Hodgkin Lymphoma?
Boyu Hu, MD
9:15 AM
What Is the Standard of Care in Second Line Hodgkin Lymphoma?
Sarah Rutherford, MD
9:35 AM
Who Benefits the Most from Radiation in Hodgkin Lymphoma?
Chelsea C. Pinnix, MD, PhD
9:55 AM
Panel Discussion, Q&A, and Postsession ARS
10:10 AM
Break and Exhibits
"Duel" Symposium: Measuring MRD Is the Standard of Care in CLL • Moderators: Timothy Fenske, MD, MS • Leo Gordon, MD
10:30 AM
Presession ARS
10:35 AM
YES - Joanna Rhodes, MD, MSCE
10:55 AM
NO - Jacob Soumerai, MD
“Dual” Symposium: Special Considerations in Treating Patients with Lymphoma
11:15 AM
AYA Patients - Ann LaCasce, MD, MMSc
11:35 AM
Elderly/Older Patients - Stefano Luminari, MD
11:55 AM
Panel Discussion, Q&A, and Postsession ARS
12:10 PM
Lunch and Exhibits
1:25 PM
Keynote Presentation: Can We Accelerate Progress in Lymphoma?
Andrew Zelenetz, MD, PhD • Moderator: Sonali Smith, MD, FASCO
Mini Symposium on Small Molecule Inhibitors in Lymphoma (2:25 PM - 3:45 PM) • Moderator: Vaishalee Kenkre, MD
2:25 PM
Presession ARS
2:30 PM
Targeting BTK: Inhibitors vs Degraders
Adam Kittai, MD
2:50 PM
PI3K: Is Targeting This Pathway Still Valuable?
Changchun Deng, MD, PhD
3:10 PM
The Next Frontier of Targeted Therapy in Lymphoma
Kami J. Maddocks, MD
3:30 PM
Panel Discussion, Q&A, and Postsession ARS
3:45 PM
Moderator: Timothy Fenske, MD, MS
Summary and Best of IUCLS
IUCLS Symposium Co-Chairs
3:55 PM
Adjourn

We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.